Status:
RECRUITING
" Visual Characterization of Parkinson's Patients and Oculomotor or Perceptual Therapy"
Lead Sponsor:
University of Valencia
Collaborating Sponsors:
Asociación Parkinson Valencia
Hospital Arnau de Vilanova
Conditions:
Parkinson Disease
Eligibility:
All Genders
30-100 years
Brief Summary
Parkinson's disease (PD) is the second most common neurodegenerative condition worldwide, characterised by motor symptoms, but with other symptoms such as visual impairment. The aim is to compare vis...
Detailed Description
Parkinson's disease (PD) is the second most common neurodegenerative condition worldwide. It is a movement disorder characterised by tremor, rigidity, bradykinesia and postural instability. However, 7...
Eligibility Criteria
Inclusion
- Subjects without neurodegenerative diseases or systemic illnesses or ocular pathologies.
- Subjects not taking medication with visual side effects.
- Subjects able to perform the tests.
- Subjects of similar age and sex as their corresponding Parkinson's patient so that both samples are age and gender matched.
- Subjects diagnosed with Parkinson's disease.
- Parkinson's patients classified according to the Hoehn \& Yahr Scale.
Exclusion
- Subjects with ocular pathologies (such as Glaucoma, Age-Related Macular Degeneration, Retinopathies, Corneal Opacifications, Senile Cataracts, Severe Palpebral Ptosis) or systemic illnesses that may affect the visual system and alter the results (such as Severe Cardiopathies, Diabetes Mellitus, oncological diseases, systemic tissue disorders, chronic infectious diseases or conditions after organ or tissue transplantation).
- Subjects with neurodegenerative or neural diseases other than the study itself, such as Alzheimer's disease, Devic's disease, Huntington's disease, Creutzfeldt-Jakob disease, epilepsy, ataxia, multiple sclerosis or amyotrophic lateral sclerosis.
- Subjects taking medication that may alter any visual ability such as anxiolytics, antidepressants, sleeping pills.
- Subjects with problems in understanding and following the tests.
- Patients who have been previously treated under a vision therapy program.
Key Trial Info
Start Date :
September 29 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT06032130
Start Date
September 29 2023
End Date
June 1 2026
Last Update
November 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Arnau de Vilanova
Valencia, Spain, 46015